Results of Trial in General Practice: Semi-Euglucon was tested in a field study by 366 general practitioners in a total of 2037 adult diabetics. The patient collective included primarily first stabilizations (56.5%), i. e. diabetics not previously treated with drugs, then transfers from sulfonyl ureas of the tolbutamide type (26.0%) and from biguanides (17.5%). During the trial period there was a significant improvement in the metabolic condition. The mean daily dose was 1.3 tablets Semi-Euglucon, small differences occurred depending on the nature of the previous treatment. After changing from the sulfonyl ureas glibornuride, glisoxepide or gliquidone the same mean daily dosage of 1.5 tablets/day was required as with the sulfonyl ureas mentioned--with considerable improvement in the metabolism.